Reacción a "A meta-analysis concludes that intravenous ketamine is effective in reducing depressive and suicidal symptoms in patients with major depression"

This is a relevant study that also uses a robust methodology: a systematic review and meta-analysis of 26 randomized clinical trials with a total of 1,166 patients with major depression. This type of analysis is considered one of the highest levels of clinical evidence because it combines results from multiple studies and provides a more precise estimate of the true treatment effect. In this case, the data reasonably support the conclusions: intravenous ketamine infusions showed a rapid and significant reduction in both depressive symptoms and suicidal ideation, with effects detectable in as little as four hours and, in some cases, lasting up to a month.

The work fits well with the evidence accumulated over the past decade, which had already pointed to ketamine as one of the few psychiatric treatments with an almost immediate antidepressant and anti-suicidal effect. The main novelty of this meta-analysis is that it updates and strengthens that evidence by incorporating more recent trials, including studies with repeated infusions, and provides a more comprehensive synthesis of both efficacy and safety. It also arrives at an important moment, following the recent approval in France of intravenous ketamine for adults with severe suicidal symptoms, which increases its clinical and regulatory relevance.

The authors made a reasonable effort to control for confounding factors. They included only randomized trials, assessed risk of bias using standard tools, and applied appropriate statistical models to handle heterogeneity across studies. Even so, there are important limitations. Many of the included trials have relatively small sample sizes, short durations, and strict selection criteria, so the results may not generalize to all patients seen in routine clinical practice. Moreover, although short-term effects are consistent, there is still uncertainty about the duration of benefit, the need for maintenance dosing, and the potential risks associated with long-term use, such as tolerance or cognitive effects.

In practical terms, the implications are significant. This study reinforces the idea that intravenous ketamine may be a valuable tool for urgent clinical situations, especially in patients with treatment-resistant depression or high suicidal risk, where conventional antidepressants often take weeks to take effect. However, it should not be interpreted as a definitive solution or a substitute for other treatments. Rather, it suggests that ketamine could become established as a rapid “rescue” intervention within specialized settings, while longer-term therapeutic strategies are put in place.